glooko Archives - Digital Health Wire

By Mark Clements, M.D., Ph.D. and Trisha Martinez , RN, BSN, MBA, Glooko

Health systems are not short on diabetes data. They are short on the time, workflows, and signal clarity needed to act on it.

That distinction matters. Continuous glucose monitoring (CGM), connected devices, remote uploads, insulin delivery data, and inpatient glucose trends are generating more information than ever before.

In Glooko’s latest Annual Diabetes Report, more than 60 billion CGM readings flowed through the platform in 2025, supported by more than 1 million active patients, 30,500 clinicians, 9,000 clinics, and a global footprint across 1,082 geographic locations.

The scale is no longer the story, but what health systems do with that scale is.

For leaders focused on digital transformation, the opportunity is to shift diabetes management from retrospective review to prioritized action.

Traditional measures such as Time in Range (TIR), Glucose Management Indicator (GMI), Time Below Range (TBR), and Time Above Range (TAR) remain essential, but they can obscure when risk occurs, how severe it is, and which patients need attention first.

Two patients may look similar by familiar metrics, yet one may face recurring overnight lows while another carries persistent daytime hyperglycemia.

The report’s overnight hypoglycemia analysis illustrates why this matters. Glooko’s model surfaced patients who appeared near target by common measures but had substantially higher overnight hypoglycemia exposure.

In validation across 586,549 patient weeks, the highest-risk group showed a 2.79x lift in identifying observed overnight hypoglycemia compared with baseline selection.

This is where digital transformation becomes clinical transformation: turning connected data into prioritized lists, cohort-level visibility, and workflows that help teams intervene between visits.

The same safety lens extends into the hospital. EndoTool provides an inpatient view of glycemic management, supporting individualized insulin dosing during complex episodes such as Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS), renal impairment, steroid exposure, and changing nutrition status.

The Takeaway

The next chapter of diabetes care will not be defined by more dashboards. It will be defined by connected intelligence that helps health systems identify risk earlier, focus clinical attention, reduce cognitive burden, and support safer decisions across the hospital, clinic, and home.

Learn how Glooko is partnering with organizations like yours to transform diabetes care.

It isn’t every week we see digital health startups score a hat trick of massive funding rounds – let alone one that rakes in a combined $295M – but Maven Clinic, Suki, and Glooko clearly came to play.

Maven Clinic kicked off the action by closing $125M of Series F funding and vaulting its valuation to $1.7B. The women’s and family health startup also gave us a behind-the-scenes peek at its 10-year roadmap:

Fertility Benefits – Maven’s fertility benefits administration product has brought millions of lives under management since launching last year, and it’s leaning in on forming more clinic partnerships to create a seamless experience between Maven’s virtual care model, financial platform, and in-person treatments.

VBC – The maternity program that serves as the bedrock of Maven’s platform is moving past “phase one” by using real-time data to engage members with a broader ecosystem of services, enabling Maven to take on full-risk and align incentives with outcomes.

Engagement – Soon-to-be-announced AI capabilities will bolster Maven’s engagement engine with more insights into fertility, maternity, and family building, as well as often-overlooked areas like return-to-work, parenting, and menopause.

Next up we saw ambient AI startup Suki land $70M of Series D financing on the heels of adding over a dozen new health systems in the past few months.

The release highlighted an expanded partnership with MedStar Health that’ll make Suki Assistant available to thousands of clinicians across specialties including primary care, cardiology, and gastroenterology.

Suki also teased plans to expand beyond its existing Suki Assistant and Suki Platform offerings, although details were sparse on what that might entail.

Glooko rounded out last week’s top scorers with a $100M Series F round and the appointment of a new CEO to guide the digital diabetes developer through its next chapter.

Freshly appointed chief Mike Alvarez will accelerate the global expansion of Glooko’s solution suite that helps diabetics take control of their condition and equips care teams with a unified platform for managing devices, data, and engagement.

The Takeaway

Digital health startups are off to a hot start in Q4, and Maven Clinic, Suki, and Glooko are the ones cranking up the heat. All signs are pointing to more late-stage mega-rounds as companies look to shore up their balance sheets and bridge the gap to a quickly thawing IPO market, unless of course they’re already eager to dive right in.

Get the top digital health stories right in your inbox